专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

EP0987022B1 CONAGENIN FOR THE TREATMENT OF ULCEROUS COLITIS AND/OR CROHN'S DISEASE 失效
标题翻译： Conagenin用于治疗溃疡性结肠炎和/或节段性回肠炎
公开(公告)号：EP0987022B1
公开(公告)日：2006-01-25
申请号：EP98912719.6
申请日：1998-04-08
申请人： ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI , TAIHO PHARMACEUTICAL CO., LTD.
发明人： ISHIZUKA, Masaaki , MAEDA, Kenji , TAKEUCHI, Tomio , SHIRAISHI, Tadayoshi , FUKUSHIMA, Masakazu
IPC分类号： A61K31/198 , A61P1/04
CPC分类号： A61K31/198 , Y10S514/885 , Y10S514/925 , Y10S514/926
摘要： Preventives and remedies for ulcerous colitis and/or Crohn's disease containing as the active ingredient conagenin or a pharmaceutically acceptable salt thereof and having prominent therapeutic effects and a high safety.

2. 发明公开

EP0987022A1 PREVENTIVES AND REMEDIES FOR ULCEROUS COLITIS AND/OR CROHN'S DISEASE 失效
标题翻译： CONAGENIN ZUR BEHANDLUNG VON ULZERATIVER KOLITIS UND / ODER MORBUS CROHN
公开(公告)号：EP0987022A1
公开(公告)日：2000-03-22
申请号：EP98912719.6
申请日：1998-04-08
申请人： ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI , TAIHO PHARMACEUTICAL CO., LTD.
发明人： ISHIZUKA, Masaaki , MAEDA, Kenji , TAKEUCHI, Tomio , SHIRAISHI, Tadayoshi , FUKUSHIMA, Masakazu
IPC分类号： A61K31/195
CPC分类号： A61K31/198 , Y10S514/885 , Y10S514/925 , Y10S514/926
摘要： Preventives and remedies for ulcerous colitis and/or Crohn's disease containing as the active ingredient conagenin or a pharmaceutically acceptable salt thereof and having prominent therapeutic effects and a high safety.
摘要翻译：溃疡性结肠炎和/或克罗恩病的预防和治疗包含作为活性成分的连接蛋白或其药学上可接受的盐，具有突出的治疗效果和高安全性。

3. 发明授权

EP2036903B1 POTENTIATOR OF RADIATION THERAPY 有权
标题翻译：增效剂放射治疗
公开(公告)号：EP2036903B1
公开(公告)日：2012-05-23
申请号：EP07790232.8
申请日：2007-06-28
申请人： Taiho Pharmaceutical Co., Ltd.
发明人： FUKUSHIMA, Masakazu
IPC分类号： C07D403/06 , A61P35/00 , A61P43/00 , A61K31/513 , A61K31/7072
CPC分类号： C07D403/06 , A61K31/513 , A61K31/7072
摘要： Disclosed is a potentiator of radiation therapy, which can reduce the dose of radiation and can also reduce adverse side-effects when used in combination with cancer radiation therapy. The potentiator comprises an uracil derivative represented by the general formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient. (1) wherein R1 represents a halogen atom or a cyano group; and R2 represents a 4- to 8-membered heterocyclic group having 1 to 3 nitrogen atoms which may have a lower alkyl group, an imino group, a hydroxyl group, a hydroxymethyl group, a methanesulfonyloxy group or an amino group as a substituent, an amidinothio group in which a hydrogen atom attached to a nitrogen atom may be substituted by a lower alkyl group, a guanidino group in which a hydrogen atom attached to a nitrogen atom may be substituted by a lower alkyl group or a cyano group, a lower alkylamidino group, or a 1-pyrrolidinylmethyl group.

4. 发明授权

EP1026173B1 ANTI-HUMAN THYMIDYLATE SYNTHASE MONOCLONAL ANTIBODIES AND HYBRIDOMAS PRODUCING THE SAME 有权
标题翻译： FOR THEIR杂交瘤细胞抗人胸苷酸合成酶的单克隆抗体和生产
公开(公告)号：EP1026173B1
公开(公告)日：2008-01-02
申请号：EP99940583.0
申请日：1999-08-31
申请人： Taiho Pharmaceutical Co., Ltd.
发明人： FUKUSHIMA, Masakazu , OKABE, Hiroyuki
IPC分类号： C07K16/40 , C12N5/20 , C12N15/06
CPC分类号： C07K16/40

5. 发明授权

EP0686641B1 2'-DEOXY-5-FLUOROURIDINE DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PROCESS FOR PRODUCING THE SAME, AND ANTITUMOR DRUG 失效
标题翻译： 2'-脱氧-5-氟尿苷，其药学上可接受的盐，AND PROCESS FOR THEIR抗肿瘤药
公开(公告)号：EP0686641B1
公开(公告)日：1998-08-26
申请号：EP95903918.1
申请日：1994-12-21
申请人： TAIHO PHARMACEUTICAL CO., LTD.
发明人： NOMURA, Makoto , KAJITANI Makoto , YAMASHITA, Junichi , FUKUSHIMA, Masakazu , SHIMAMOTO, Yuji
IPC分类号： C07H19/073 , A61K31/70
CPC分类号： C07H19/06 , Y10S514/908

6. 发明公开

EP2431032A1 ANTI-TUMOR AGENT COMPRISING TEGAFUR-GIMERACIL-OTERACIL POTASSIUM COMBINATION DRUG AND OXALIPLATIN 审中-公开
标题翻译：奥地利麻醉品麻醉品麻醉品联合会TEGAFUR-GIMERACIL-OTERACIL-KALIUM-KOMBINATION
公开(公告)号：EP2431032A1
公开(公告)日：2012-03-21
申请号：EP10774719.8
申请日：2010-05-11
申请人： Taiho Pharmaceutical Co., Ltd.
发明人： FUKUSHIMA, Masakazu
IPC分类号： A61K31/282 , A61K31/404 , A61K31/4412 , A61K31/513 , A61K31/53 , A61P35/00
CPC分类号： A61K31/4412 , A61K31/282 , A61K31/404 , A61K31/513 , A61K31/53 , A61K2300/00
摘要： To provide a novel combination therapy which exhibits remarkable anti-tumor effect.
The invention provides an anti-tumor agent comprising a combination drug containing tegafur, gimeracil and oteracil potassium, oxaliplatin, and TSU-68 or a salt thereof, in combination.
摘要翻译：提供一种具有显着抗肿瘤作用的新型联合疗法。本发明组合提供包含组合药物的抗肿瘤剂，其包含替加氟，吉美脯氨酸和奥特拉西钾，奥沙利铂和TSU-68或其盐。

7. 发明授权

EP2045258B1 3'-ETHYNYLCYTIDINE DERIVATIVE 有权
标题翻译： 3'-乙炔基鞘氨醇衍生物
公开(公告)号：EP2045258B1
公开(公告)日：2011-09-21
申请号：EP07790281.5
申请日：2007-07-23
申请人： Taiho Pharmaceutical Co., Ltd. , Sasaki, Takuma , Matsuda, Akira
发明人： TANAKA, Motoaki , FUKUSHIMA, Masakazu
IPC分类号： C07H23/00 , A61K31/7068 , A61P35/00 , A61P35/02 , C07H19/06
CPC分类号： C07H19/06
摘要： Disclosed is a compound which has excellent anti-tumor activity and excellent oral absorbability and is useful as an anti-tumor agent. Specifically disclosed is a 3'-ethynylcytidine derivative represented by the general formula (1) [wherein X represents a (substituted) alkylcarbonyl group, a (substituted) alkoxycarbonyl group or a hydrogen atom; one of Y and Z represents a hydrogen atom or a group represented by the formula: (R1)(R2)(R3)Si- and the other represents a group represented by the formula: (R4)(R5)(R6)Si-; and R1, R2, R3, R4, R5 and R6 independently represent a (substituted) alkyl group, a (substituted) cyclic alkyl group or a (substituted) aryl group] or a salt thereof.
摘要翻译：公开了具有优异的抗肿瘤活性和优异的口服吸收性并且可用作抗肿瘤剂的化合物。具体公开了由通式（1）表示的3'-乙炔基胞嘧啶核苷衍生物[其中X代表（取代）烷基羰基，（取代）烷氧基羰基或氢原子; Y和Z中的一个表示氢原子或由式：（R 1）（R 2）（R 3）Si-表示的基团，并且另一个表示由式：（R 4）（R 5）（R 6）Si- ; 并且R 1，R 2，R 3，R 4，R 5和R 6独立地表示（取代的）烷基，（取代的）环烷基或（取代的）芳基]或其盐。

8. 发明公开

EP2036903A1 POTENTIATOR OF RADIATION THERAPY 有权
标题翻译：电位器FÜRDIE STRAHLENTHERAPIE
公开(公告)号：EP2036903A1
公开(公告)日：2009-03-18
申请号：EP07790232.8
申请日：2007-06-28
申请人： Taiho Pharmaceutical Co., Ltd.
发明人： FUKUSHIMA, Masakazu
IPC分类号： C07D403/06 , A61P35/00 , A61P43/00 , A61K31/513 , A61K31/7072
CPC分类号： C07D403/06 , A61K31/513 , A61K31/7072
摘要： To provide a radiation therapy potentiator, which, when employed in combination with cancer radiation therapy, can reduce radiation dose and can mitigate adverse effects.
The invention provides a radiation therapy potentiator containing, as an effective ingredient, a uracil derivative represented by formula (1) (wherein R 1 represents a halogen atom or a cyano group; and R 2 represents a 4- to 8-membered heterocyclic group having 1 to 3 nitrogen atoms and optionally having as a substituent a lower alkyl group, an imino group, a hydroxyl group, a hydroxymethyl group, a methanesulfonyloxy group, or an amino group; an amidinothio group in which a hydrogen atom attached to a nitrogen atom may be substituted by a lower alkyl group; a guanidino group in which a hydrogen atom attached to a nitrogen atom may be substituted by a lower alkyl group or a cyano group; a lower alkylamidino group; or a 1-pyrrolidinylmethyl group) or a pharmaceutically acceptable salt thereof.
摘要翻译：提供放射治疗增强剂，当与癌症放射治疗组合使用时，可以减少辐射剂量并减轻不良反应。本发明提供一种放射治疗增效剂，其含有作为有效成分的式（1）表示的尿嘧啶衍生物（其中，R 1表示卤素原子或氰基），R 2表示4〜8元杂环基， 1〜3个氮原子，任选具有低级烷基，亚氨基，羟基，羟甲基，甲磺酰氧基或氨基作为取代基;脒基硫基，其中连接到氮原子上的氢原子可以被低级烷基取代;其中与氮原子连接的氢原子可以被低级烷基或氰基取代的胍基，低级烷基脒基或1-吡咯烷基甲基）或药学上可接受的盐其可接受的盐。

9. 发明授权

EP1230925B8 USE OF A TRIFLURIDINE DERIVATIVE ALONE OR COMBINED WITH A THYMIDINE PHOSPHORYLASE INHIBITOR FOR THE TREATMENT OF HIV 有权
标题翻译：甲三氟胸苷衍生物的用途单独使用或组合WITH A胸苷磷酸化酶抑制剂用于治疗HIV的
公开(公告)号：EP1230925B8
公开(公告)日：2006-03-01
申请号：EP00971704.2
申请日：2000-11-01
申请人： TAIHO PHARMACEUTICAL CO., LTD.
发明人： HOSHINO, Hiroo , KITAZATO, Kenji , FUKUSHIMA, Masakazu
IPC分类号： A61K31/7072 , A61K31/513 , A61K31/506 , A61P31/18
CPC分类号： A61K31/7072 , A61K31/506 , A61K31/513 , A61K45/06 , A61K2300/00
摘要： An anti-HIV composition containing at least one member selected from the group consisting of trifluridine and derivatives thereof and a pharmaceutically acceptable carrier; an anti-HIV composition containing as the active ingredients (a) at least one member selected from the group consisting of trifluridine and derivatives thereof, (b) a thymidine phosphorylase inhibitor, and a pharmaceutically acceptable carrier; and a composition for potentiating the anti-HIV activity of trifluridine or derivatives thereof, containing a thymidine phosphorylase inhibitor and a pharmaceutically acceptable carrier.

10. 发明公开

EP2045258A1 3'-ETHYNYLCYTIDINE DERIVATIVE 有权
标题翻译： 3'-乙炔基鞘氨醇衍生物
公开(公告)号：EP2045258A1
公开(公告)日：2009-04-08
申请号：EP07790281.5
申请日：2007-07-23
申请人： Taiho Pharmaceutical Co., Ltd. , Sasaki, Takuma , Matsuda, Akira
发明人： TANAKA, Motoaki , FUKUSHIMA, Masakazu
IPC分类号： C07H23/00 , A61K31/7068 , A61P35/00 , A61P35/02 , C07H19/06
CPC分类号： C07H19/06
摘要： To provide a compound which exhibits excellent anti-tumor activity and excellent oral absorption and which is a useful anti-tumor drug.
The invention provides a 3'-ethynylcytidine derivative represented by formula (1):

(wherein X represents a (substituted) alkylcarbonyl group, a (substituted) alkoxycarbonyl group, or a hydrogen atom; one of Y and Z represents a hydrogen atom or a group represented by (R 1 ) (R 2 ) (R 3 )Si- and the other represents a group represented by (R 4 ) (R 5 ) (R 6 )Si-; and R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 each represent a (substituted) alkyl group, a (substituted) cyclic alkyl group, or a (substituted) aryl group) or a salt thereof.
摘要翻译：提供具有优异的抗肿瘤活性和优异的口服吸收性并且是有用的抗肿瘤药物的化合物。本发明提供由式（1）表示的3'-乙炔基胞嘧啶核苷衍生物：（其中X代表（取代）烷基羰基，（取代）烷氧基羰基或氢原子; Y和Z中的一个代表氢原子或（R 1）（R 2）（R 3）Si-表示的基团，另一个表示由（R 4）（R 5）（R 6）Si-表示的基团;并且R 1，R 2，R 3，R 4，R 5和R 6各自表示（取代）烷基，（取代）环状烷基或（取代）芳基）或其盐。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式